BioSante Female Libido Drug Hype Was Fraudulent: Suit
An investor hit BioSante Pharmaceuticals Inc. with a securities fraud class action Friday in Illinois claiming CEO Stephen Simes told tall tales about how an experimental women's libido drug was bound...To view the full article, register now.
Already a subscriber? Click here to view full article